{"filing":{"accession_number":"0001628280-26-054266","cik":"0001611115","ticker":"OMDA","company_name":"Omada Health, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"omda-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611115/000162828026054266/omda-20260806.htm"},"events":[{"id":25882,"run_id":23499,"accession_number":"0001628280-26-054266","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Omada Health issued a press release on August 6, 2026 announcing Q2 2026 financial results, including revenue of $88 million (43% YoY growth), gross margin of 73%, and net income of $5 million, with forward guidance for full-year 2026.","company_name":"Omada Health, Inc.","ticker":"OMDA","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26816,"accession_number":"0001628280-26-054266","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Omada Health issued a press release on August 6, 2026 announcing Q2 2026 financial results, including revenue of $88 million (43% YoY growth), gross margin of 73%, and net income of $5 million. The filing explicitly states this is Item 2.02 disclosure with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes detailed financial highlights, operational metrics, and forward guidance for full-year 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:40:48.832307+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25883,"run_id":23499,"accession_number":"0001628280-26-054266","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Effective January 1, 2027, Wei-Li Shao will be appointed as Chief Executive Officer and Class I director, Sean Duffy will transition to Executive Chairman, and Jeryl Hilleman will be appointed as Lead Independent Director.","company_name":"Omada Health, Inc.","ticker":"OMDA","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26817,"accession_number":"0001628280-26-054266","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a leadership transition effective January 1, 2027, in which Wei-Li Shao, the current President, will be appointed as Chief Executive Officer, and Sean Duffy will transition to Executive Chairman. Additionally, Jeryl Hilleman is appointed as Lead Independent Director. While the filing also involves Duffy's departure from the CEO role, the principal disclosed action centers on Shao's appointment to the CEO position and his concurrent appointment as a Class I director, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:40:48.832307+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26816,"accession_number":"0001628280-26-054266","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Omada Health issued a press release on August 6, 2026 announcing Q2 2026 financial results, including revenue of $88 million (43% YoY growth), gross margin of 73%, and net income of $5 million. The filing explicitly states this is Item 2.02 disclosure with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes detailed financial highlights, operational metrics, and forward guidance for full-year 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:40:48.832307+00:00","company_name":"Omada Health, Inc.","ticker":"OMDA","filing_date":"2026-08-06"},{"id":26817,"accession_number":"0001628280-26-054266","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a leadership transition effective January 1, 2027, in which Wei-Li Shao, the current President, will be appointed as Chief Executive Officer, and Sean Duffy will transition to Executive Chairman. Additionally, Jeryl Hilleman is appointed as Lead Independent Director. While the filing also involves Duffy's departure from the CEO role, the principal disclosed action centers on Shao's appointment to the CEO position and his concurrent appointment as a Class I director, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:40:48.832307+00:00","company_name":"Omada Health, Inc.","ticker":"OMDA","filing_date":"2026-08-06"}]}